Whereas structurally dissimilar D1 antagonists competing for [3H]-SCH23390 binding recognize primarily one site in striatum, two distinct affinity states are observed in both amygdala and hippocampus. The binding profile of SCH23390 is similar in both of these regions, with the high affinity site (KD ∼ 0.4 nM) consistent with D1/D5 receptors. The appearance of the low affinity site (KD ∼ 300 nM) is dependent upon the absence of MgCl2, but independent of D1 expression (i.e., still present in D1 knockout mice). Although the density of high affinity state receptor is lower in hippocampus or amygdala of D1 knockout mice, some residual binding remains, consistent with the known expression of D5 receptors in these regions. Remarkably, in hippocampus, the affinity of the low affinity site is shifted rightward in the presence of the D2 antagonist domperidone and is largely absent in the hippocampus of D2 knockout animals. Additionally, this site is also shifted rightward in the presence of the A2A ligands SCH58261, CSC, or NECA, or in the absence of A2A receptors. The affinity of SCH23390 for this low affinity site is greater than seen for SCH23390 binding to D2 receptors in heterologous expression systems, consistent with the hypothesis that both D2 and A2A receptors are involved in the low affinity binding site. Therefore, we suggest that the heteromerization of D2 and A2A receptors reported previously in vitro also may occur in the brain of both rats and mice.
All Science Journal Classification (ASJC) codes
- Molecular Biology
- Clinical Neurology
- Developmental Biology